Skip to main content
Springer Nature Link
Log in

Approach to risk stratification in testicular germ cell tumors: a primer for radiologists

  • Pictorial Essay
  • Published:
Abdominal Imaging Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Oncologists increasingly exploit differences in testicular germ cell tumors to deliver more personalized treatment. Imaging is essential in this process, aiding in the selection of risk-stratified management strategies. Consideration of relevant prognostic factors strengthens image interpretation, allowing for a more nuanced radiographic evaluation. This paper uses a clinically focused, stage-by-stage approach to delineate the risk factors for relapse and metastasis that radiologists should consider during staging, response assessment, and surveillance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. Shanmugalingam T, Soultati A, Chowdhury S, Rudman S, Van Hemelrijck M (2013) Global incidence and outcome of testicular cancer. Clin Epidemiol 5:417–427. doi:10.2147/clep.s34430

    PubMed Central  PubMed  Google Scholar 

  2. Znaor A, Lortet-Tieulent J, Jemal A, Bray F (2013) International variations and trends in testicular cancer incidence and mortality. Eur Urol . doi:10.1016/j.eururo.2013.11.004

    PubMed  Google Scholar 

  3. Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29. doi:10.3322/caac.21208

    Article  PubMed  Google Scholar 

  4. Ulbright TM, Amin MB, Young RH (1999) Tumors of the testis, adnexa, spermatic cord and scrotum. In: Rosai J, Sobin LH (eds) Atlas of tumor pathology, fasc 25, ser 3. Washington, DC: Armed Forces Institute of Pathology, pp 1–290

    Google Scholar 

  5. Klepp O, Flodgren P, Maartman-Moe H, et al. (1990) Early clinical stages (CS1, CS1Mk+ and CS2A) of non-seminomatous testis cancer. Value of pre- and post-orchiectomy serum tumor marker information in prediction of retroperitoneal lymph node metastases. Swedish-Norwegian Testicular Cancer Project (SWENOTECA). Ann Oncol 1(4):281–288

    CAS  PubMed  Google Scholar 

  6. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ (2008) Medical treatment of advanced testicular cancer. J Am Med Assoc 299(6):672–684. doi:10.1001/jama.299.6.672

    Article  CAS  Google Scholar 

  7. Rifkin MD, Kurtz AB, Pasto ME, Goldberg BB (1985) Diagnostic capabilities of high-resolution scrotal ultrasonography: prospective evaluation. J Ultrasound Med 4(1):13–19

    CAS  PubMed  Google Scholar 

  8. Schwerk WB, Schwerk WN, Rodeck G (1987) Testicular tumors: prospective analysis of real-time US patterns and abdominal staging. Radiology 164(2):369–374. doi:10.1148/radiology.164.2.3299487

    Article  CAS  PubMed  Google Scholar 

  9. Dogra VS, Gottlieb RH, Oka M, Rubens DJ (2003) Sonography of the scrotum. Radiology 227(1):18–36. doi:10.1148/radiol.2271001744

    Article  PubMed  Google Scholar 

  10. Carkaci S, Ozkan E, Lane D, Yang WT (2010) Scrotal sonography revisited. J Clin Ultrasound JCU 38(1):21–37. doi:10.1002/jcu.20642

    PubMed  Google Scholar 

  11. Marth D, Scheidegger J, Studer UE (1990) Ultrasonography of testicular tumors. Urol Int 45(4):237–240

    Article  CAS  PubMed  Google Scholar 

  12. Gross AJ, Heinzer H, Loy V, Dieckmann KP (1992) Unusual differential diagnosis of testis tumor: intrascrotal sarcoidosis. J Urol 147(4):1112–1114

    CAS  PubMed  Google Scholar 

  13. Basekim CC, Kizilkaya E, Pekkafali Z, Baykal KV, Karsli AF (2000) Mumps epididymo-orchitis: sonography and color Doppler sonographic findings. Abdom Imaging 25(3):322–325

    Article  CAS  PubMed  Google Scholar 

  14. Serra AD, Hricak H, Coakley FV, et al. (1998) Inconclusive clinical and ultrasound evaluation of the scrotum: impact of magnetic resonance imaging on patient management and cost. Urology 51(6):1018–1021

    Article  CAS  PubMed  Google Scholar 

  15. Tsili AC, Argyropoulou MI, Giannakis D, Sofikitis N, Tsampoulas K (2010) MRI in the characterization and local staging of testicular neoplasms. AJR Am J Roentgenol 194(3):682–689. doi:10.2214/ajr.09.3256

    Article  PubMed  Google Scholar 

  16. AJCC (2010) Ophthalmic Oncology Task Force. Sarcoma of the orbit. In: Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) AJCC cancer staging manual, 7th edn. New York: Springer, pp 469–478

    Google Scholar 

  17. Weiss RM, George NJR, O’Reilly PH (2001) Comprehensive urology. London: Mosby

    Google Scholar 

  18. Donohue JP, Zachary JM, Maynard BR (1982) Distribution of nodal metastases in nonseminomatous testis cancer. J Urol 128(2):315–320

    CAS  PubMed  Google Scholar 

  19. Motzer RJ, Agarwal N, Beard C, et al. (2012) Testicular cancer. J Natl Compr Cancer Netw JNCCN 10(4):502–535

    CAS  PubMed  Google Scholar 

  20. See WA, Hoxie L (1993) Chest staging in testis cancer patients: imaging modality selection based upon risk assessment as determined by abdominal computerized tomography scan results. J Urol 150(3):874–878

    CAS  PubMed  Google Scholar 

  21. Horan G, Rafique A, Robson J, Dixon AK, Williams MV (2007) CT of the chest can hinder the management of seminoma of the testis; it detects irrelevant abnormalities. Br J Cancer 96(6):882–885. doi:10.1038/sj.bjc.6603657

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. White PM, Adamson DJ, Howard GC, Wright AR (1999) Imaging of the thorax in the management of germ cell testicular tumours. Clin Radiol 54(4):207–211

    Article  CAS  PubMed  Google Scholar 

  23. Tandstad T, Dahl O, Cohn-Cedermark G, et al. (2009) Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol 27(13):2122–2128. doi:10.1200/jco.2008.18.8953

    Article  PubMed  Google Scholar 

  24. Albers P, Siener R, Krege S, et al. (2008) Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 26(18):2966–2972. doi:10.1200/jco.2007.12.0899

    Article  CAS  PubMed  Google Scholar 

  25. Horwich A, Alsanjari N, A’Hern R, et al. (1992) Surveillance following orchidectomy for stage I testicular seminoma. Br J Cancer 65(5):775–778

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. von der Maase H, Specht L, Jacobsen GK, et al. (1993) Surveillance following orchidectomy for stage I seminoma of the testis. Eur J Cancer (Oxf) 29(14):1931–1934

  27. Germa-Lluch JR, Garcia del Muro X, Maroto P, et al. (2002) Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG). Eur Urol 42(6):553–562; discussion 562–553

  28. Daugaard G, Petersen PM, Rorth M (2003) Surveillance in stage I testicular cancer. APMIS 111(1):76–83; discussion 83–75

  29. Tyldesley S, Voduc D, McKenzie M, et al. (2006) Surveillance of stage I testicular seminoma: British Columbia Cancer Agency Experience 1992 to 2002. Urology 67(3):594–598. doi:10.1016/j.urology.2005.09.050

    Article  PubMed  Google Scholar 

  30. Leung E, Warde P, Jewett M, et al. (2013) Treatment burden in stage I seminoma: a comparison of surveillance and adjuvant radiation therapy. BJU Int 112(8):1088–1095. doi:10.1111/bju.12330

    Article  PubMed  Google Scholar 

  31. Oliver RT, Mason MD, Mead GM, et al. (2005) Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 366(9482):293–300. doi:10.1016/s0140-6736(05)66984-x

    Article  CAS  PubMed  Google Scholar 

  32. Albers P, Siener R, Kliesch S, et al. (2003) Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol 21(8):1505–1512. doi:10.1200/jco.2003.07.169

    Article  PubMed  Google Scholar 

  33. Williams SB, Kacker R, Winston D, et al. (2011) Predictors of positive retroperitoneal lymph nodes in patients with high risk testicular cancer. J Urol 186(6):2245–2248. doi:10.1016/j.juro.2011.07.101

    Article  CAS  PubMed  Google Scholar 

  34. Krege S, Beyer J, Souchon R, et al. (2008) European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol 53(3):478–496. doi:10.1016/j.eururo.2007.12.024

    Article  PubMed  Google Scholar 

  35. Sweeney CJ, Hermans BP, Heilman DK, et al. (2000) Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma—predominant testis cancer. J Clin Oncol 18(2):358–362

    CAS  PubMed  Google Scholar 

  36. Vergouwe Y, Steyerberg EW, Eijkemans MJ, Albers P, Habbema JD (2003) Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review. J Clin Oncol 21(22):4092–4099. doi:10.1200/jco.2003.01.094

    Article  PubMed  Google Scholar 

  37. Stephenson AJ, Sheinfeld J (2005) Management of patients with low-stage nonseminomatous germ cell testicular cancer. Curr Treat Options Oncol 6(5):367–377

    Article  PubMed  Google Scholar 

  38. Howard S, Gray K, Fennessey F, et al. (2014) Craniocaudal retroperitoneal node length as a risk factor for relapse from clinical stage I testicular germ cell tumor. Am J Roentgenol 203:W415–W420

    Article  Google Scholar 

  39. Warde P, Specht L, Horwich A, et al. (2002) Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 20(22):4448–4452

    Article  PubMed  Google Scholar 

  40. Rustin GJ, Mead GM, Stenning SP, et al. (2007) Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197—the National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol 25(11):1310–1315. doi:10.1200/jco.2006.08.4889

    Article  PubMed  Google Scholar 

  41. Chung PW, Bedard P (2011) Stage II seminomas and nonseminomas. Hematol Oncol Clin N Am 25(3):529–541, viii. doi:10.1016/j.hoc.2011.03.009

  42. Chung P, Warde P (2013) Contemporary management of stage I and II seminoma. Curr Urol Rep 14(5):525–533. doi:10.1007/s11934-013-0365-2

    Article  PubMed  Google Scholar 

  43. Classen J, Schmidberger H, Meisner C, et al. (2003) Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 21(6):1101–1106

    Article  PubMed  Google Scholar 

  44. Chung PW, Gospodarowicz MK, Panzarella T, et al. (2004) Stage II testicular seminoma: patterns of recurrence and outcome of treatment. Eur Urol 45(6):754–759; discussion 759–760. doi:10.1016/j.eururo.2004.01.020

  45. Thomas GM (1997) Over 20 years of progress in radiation oncology: seminoma. Semin Radiat Oncol 7(2):135–145. doi:10.1053/srao00700135

    Article  PubMed  Google Scholar 

  46. Hilton S, Herr HW, Teitcher JB, Begg CB, Castellino RA (1997) CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: assessment of size and distribution criteria. AJR Am J Roentgenol 169(2):521–525. doi:10.2214/ajr.169.2.9242768

    Article  CAS  PubMed  Google Scholar 

  47. Hudolin T, Kastelan Z, Knezevic N, et al. (2012) Correlation between retroperitoneal lymph node size and presence of metastases in nonseminomatous germ cell tumors. Int J Surg Pathol 20(1):15–18. doi:10.1177/1066896911431452

    Article  PubMed  Google Scholar 

  48. Donohue JP, Thornhill JA, Foster RS, et al. (1995) The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University experience (1965 to 1989). J Urol 153(1):85–89

    Article  CAS  PubMed  Google Scholar 

  49. Stephenson AJ, Bosl GJ, Motzer RJ, et al. (2007) Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. J Clin Oncol 25(35):5597–5602. doi:10.1200/jco.2007.12.0808

    Article  PubMed  Google Scholar 

  50. Williams SD, Stablein DM, Einhorn LH, et al. (1987) Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 317(23):1433–1438. doi:10.1056/nejm198712033172303

    Article  CAS  PubMed  Google Scholar 

  51. Sohaib SA, Koh DM, Barbachano Y, et al. (2009) Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours. Clin Radiol 64(4):362–367. doi:10.1016/j.crad.2008.10.011

    Article  CAS  PubMed  Google Scholar 

  52. Hogeboom WR, Hoekstra HJ, Mooyaart EL, et al. (1991) The role of magnetic resonance imaging and computed tomography in the treatment evaluation of retroperitoneal lymph-node metastases of non-seminomatous testicular tumors. Eur J Radiol 13(1):31–36

    Article  CAS  PubMed  Google Scholar 

  53. Harisinghani MG, Saksena M, Ross RW, et al. (2005) A pilot study of lymphotrophic nanoparticle-enhanced magnetic resonance imaging technique in early stage testicular cancer: a new method for noninvasive lymph node evaluation. Urology 66(5):1066–1071. doi:10.1016/j.urology.2005.05.049

    Article  PubMed  Google Scholar 

  54. Eiber M, Beer AJ, Holzapfel K, et al. (2010) Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MR-imaging. Invest Radiol 45(1):15–23. doi:10.1097/RLI.0b013e3181bbdc2f

    Article  PubMed  Google Scholar 

  55. Huddart RA, O’Doherty MJ, Padhani A, et al. (2007) 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22—the NCRI Testis Tumour Clinical Study Group. J Clin Oncol 25(21):3090–3095. doi:10.1200/jco.2006.09.3831

    Article  PubMed  Google Scholar 

  56. de Wit M, Brenner W, Hartmann M, et al. (2008) [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. Ann Oncol 19(9):1619–1623. doi:10.1093/annonc/mdn170

    Article  PubMed  Google Scholar 

  57. Einhorn LH, Donohue J (1977) Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87(3):293–298

    Article  CAS  PubMed  Google Scholar 

  58. International Germ Cell Cancer Collaborative Group (1997) International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15(2):594–603

  59. Carver BS, Sheinfeld J (2005) Germ cell tumors of the testis. Ann Surg Oncol 12(11):871–880. doi:10.1245/aso.2005.01.013

    Article  PubMed  Google Scholar 

  60. Bredael JJ, Vugrin D, Whitmore WF Jr (1982) Autopsy findings in 154 patients with germ cell tumors of the testis. Cancer 50(3):548–551

    Article  CAS  PubMed  Google Scholar 

  61. Lorch A, Beyer J, Bascoul-Mollevi C, et al. (2010) Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol 28(33):4906–4911. doi:10.1200/jco.2009.26.8128

    Article  PubMed  Google Scholar 

  62. Sohaib SA, Cook G, Koh DM (2011) Imaging studies for germ cell tumors. Hematol Oncol Clin N Am 25(3):487–502, vii. doi:10.1016/j.hoc.2011.03.014

  63. Wood A, Robson N, Tung K, Mead G (1996) Patterns of supradiaphragmatic metastases in testicular germ cell tumours. Clin Radiol 51(4):273–276

    Article  CAS  PubMed  Google Scholar 

  64. Dalal PU, Sohaib SA, Huddart R (2006) Imaging of testicular germ cell tumours. Cancer Imaging 6:124–134. doi:10.1102/1470-7330.2006.0020

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  65. Brunereau L, Bruyere F, Linassier C, Baulieu JL (2012) The role of imaging in staging and monitoring testicular cancer. Diagn Interv Imaging 93(4):310–318. doi:10.1016/j.diii.2012.01.014

    Article  CAS  PubMed  Google Scholar 

  66. Boyle HJ, Jouanneau E, Droz JP, Flechon A (2013) Management of brain metastases from germ cell tumors: a single center experience. Oncology 85(1):21–26. doi:10.1159/000351812

    Article  CAS  PubMed  Google Scholar 

  67. Oechsle K, Bokemeyer C (2011) Treatment of brain metastases from germ cell tumors. Hematol Oncol Clin N Am 25(3):605–613, ix. doi:10.1016/j.hoc.2011.03.012

  68. Oechsle K, Bokemeyer C, Kollmannsberger C, et al. (2012) Bone metastases in germ cell tumor patients. J Cancer Res Clin Oncol 138(6):947–952. doi:10.1007/s00432-012-1169-3

    Article  CAS  PubMed  Google Scholar 

  69. Hitchins RN, Philip PA, Wignall B, et al. (1988) Bone disease in testicular and extragonadal germ cell tumours. Br J Cancer 58(6):793–796

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  70. Jamal-Hanjani M, Karpathakis A, Kwan A, et al. (2013) Bone metastases in germ cell tumours: lessons learnt from a large retrospective study. BJU Int 112(2):176–181. doi:10.1111/bju.12218

    Article  CAS  PubMed  Google Scholar 

  71. Rajarubendra N, Bolton D, Lawrentschuk N (2010) Diagnosis of bone metastases in urological malignancies—an update. Urology 76(4):782–790. doi:10.1016/j.urology.2009.12.050

    Article  PubMed  Google Scholar 

  72. Puc HS, Heelan R, Mazumdar M, et al. (1996) Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol 14(2):454–460

    CAS  PubMed  Google Scholar 

  73. Becherer A, De Santis M, Karanikas G, et al. (2005) FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. Eur J Radiol 54(2):284–288. doi:10.1016/j.ejrad.2004.07.012

    Article  PubMed  Google Scholar 

  74. Bachner M, Loriot Y, Gross-Goupil M, et al. (2012) 2-(1)(8)Fluoro-deoxy-d-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol 23(1):59–64. doi:10.1093/annonc/mdr052

    Article  CAS  PubMed  Google Scholar 

  75. Daneshmand S, Albers P, Fossa SD, et al. (2012) Contemporary management of postchemotherapy testis cancer. Eur Urol 62(5):867–876. doi:10.1016/j.eururo.2012.08.014

    Article  PubMed  Google Scholar 

  76. Beyer J, Albers P, Altena R, et al. (2013) Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol 24(4):878–888. doi:10.1093/annonc/mds579

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  77. Fox EP, Weathers TD, Williams SD, et al. (1993) Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol 11(7):1294–1299

    CAS  PubMed  Google Scholar 

  78. Steyerberg EW, Keizer HJ, Sleijfer DT, et al. (2000) Retroperitoneal metastases in testicular cancer: role of CT measurements of residual masses in decision making for resection after chemotherapy. Radiology 215(2):437–444. doi:10.1148/radiology.215.2.r00ma02437

    Article  CAS  PubMed  Google Scholar 

  79. Oechsle K, Hartmann M, Brenner W, et al. (2008) [18F]Fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German multicenter positron emission tomography study group. J Clin Oncol 26(36):5930–5935. doi:10.1200/jco.2008.17.1157

    Article  PubMed  Google Scholar 

  80. Kollmannsberger C, Oechsle K, Dohmen BM, et al. (2002) Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma. Cancer 94(9):2353–2362. doi:10.1002/cncr.10494

    Article  PubMed  Google Scholar 

  81. Stephens AW, Gonin R, Hutchins GD, Einhorn LH (1996) Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol 14(5):1637–1641

    CAS  PubMed  Google Scholar 

  82. Sugawara Y, Zasadny KR, Grossman HB, et al. (1999) Germ cell tumor: differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling. Radiology 211(1):249–256. doi:10.1148/radiology.211.1.r99ap16249

    Article  CAS  PubMed  Google Scholar 

  83. Pfannenberg AC, Oechsle K, Bokemeyer C, et al. (2004) The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors—prospects for management. World J Urol 22(2):132–139. doi:10.1007/s00345-003-0392-6

    Article  CAS  PubMed  Google Scholar 

  84. Krege S, Beyer J, Souchon R, et al. (2008) European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol 53(3):497–513. doi:10.1016/j.eururo.2007.12.025

    Article  PubMed  Google Scholar 

  85. Oto A, Yacoub JH, Casalino DD, et al. (2012) ACR Appropriateness Criteria® staging of testicular malignancy. Am Coll Radiol. https://acsearch.acr.org/docs/69375/Narrative/. Accessed November 12, 2014

  86. Petralia G, Thoeny HC (2010) DW-MRI of the urogenital tract: applications in oncology. Cancer Imaging 10(Spec no A):S112–123. doi:10.1102/1470-7330.2010.9030

  87. Gilbert DC, Chandler I, McIntyre A, et al. (2009) Clinical and biological significance of CXCL12 and CXCR4 expression in adult testes and germ cell tumours of adults and adolescents. J Pathol 217(1):94–102. doi:10.1002/path.2436

    Article  CAS  PubMed  Google Scholar 

  88. Mayer F, Gillis AJ, Dinjens W, et al. (2002) Microsatellite instability of germ cell tumors is associated with resistance to systemic treatment. Cancer Res 62(10):2758–2760

    CAS  PubMed  Google Scholar 

  89. Velasco A, Corvalan A, Wistuba II, et al. (2008) Mismatch repair expression in testicular cancer predicts recurrence and survival. Int J Cancer 122(8):1774–1777. doi:10.1002/ijc.23291

    Article  CAS  PubMed  Google Scholar 

  90. Honecker F, Wermann H, Mayer F, et al. (2009) Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol 27(13):2129–2136. doi:10.1200/jco.2008.18.8623

    Article  CAS  PubMed  Google Scholar 

  91. Ruf CG, Linbecker M, Port M, et al. (2012) Predicting metastasized seminoma using gene expression. BJU Int 110(2 Pt 2):E14–E20. doi:10.1111/j.1464-410X.2011.10778.x

    Article  CAS  PubMed  Google Scholar 

  92. Korkola JE, Houldsworth J, Feldman DR, et al. (2009) Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors. J Clin Oncol 27(31):5240–5247. doi:10.1200/jco.2008.20.0386

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Harvard Medical School, 25 Shattuck St, Boston, MA, 02115, USA

    Monica J. Wood

  2. Department of Imaging, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA

    Sree Harsha Tirumani, Nikhil H. Ramaiya & Stephanie A. Howard

  3. Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA

    Sree Harsha Tirumani, Nikhil H. Ramaiya & Stephanie A. Howard

  4. Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA

    Christopher Sweeney

Authors
  1. Monica J. Wood
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Sree Harsha Tirumani
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Christopher Sweeney
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Nikhil H. Ramaiya
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Stephanie A. Howard
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Monica J. Wood.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wood, M.J., Tirumani, S.H., Sweeney, C. et al. Approach to risk stratification in testicular germ cell tumors: a primer for radiologists. Abdom Imaging 40, 1871–1886 (2015). https://doi.org/10.1007/s00261-014-0304-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00261-014-0304-9

Keywords